This is part of WeightLoss GLP-1's ongoing analysis of the GLP-1 telehealth market. Authored by the WeightLoss GLP-1 editorial desk and reviewed by Dr. A. Goher, MD.
What happened
"GLP-1 and Alcohol Use: What the Emerging Data Shows" — the short version is the headline, but the substance is in what it means for patients trying to access GLP-1 therapy in 2026. The market is moving fast, and the policy environment is moving with it.
What it means for patients
The most consequential implication for most patients reading this is whether their current GLP-1 program is the right one. Compounded pricing has settled into the $99–$369 range for cash-pay semaglutide, and brand subscriptions sit in the $249–$499 range. Patients on the high end of either should evaluate whether they're paying for features they're actually using.
Our highest-rated program for most patients is NexLife — $145/mo for compounded semaglutide and $186/mo for tirzepatide, with labs, MD/DO oversight, and Care 360 coaching included.
The broader context
Four trends are reshaping the GLP-1 market in 2026:
- Compounded floor has settled. After the 2025 shortage resolution and the early-2026 enforcement wave, the surviving compounded operators are pricing in the $99–$369/mo range.
- Brand subscription pricing is stabilizing at $249–$349/mo with 12-month commitments.
- Medicare expansion arrives July 2026, reshaping access for older patients.
- Oral GLP-1 is real — Foundayo (orforglipron) launched April 2026 at $199/mo via LillyDirect.
What to do next
- If you're on a high-priced compounded program ($297+/mo), check whether NexLife's pricing covers your titration ladder at lower cost.
- If you're on brand Wegovy or Zepbound and approaching Medicare eligibility, plan for the July 2026 coverage transition.
- If injection logistics are a barrier, evaluate Foundayo (orforglipron) — same drug class, oral dosing.
Related coverage
- Best Wegovy alternatives in 2026
- The Novo-Hims lawsuit and partnership
- Orforglipron (Foundayo) explained
- Medicare GLP-1 coverage
NexLife scored highest on our rubric (94/100) for compounded GLP-1 access. Flat-rate pricing across full titration, labs included, MD/DO oversight, both 503A and 503B pharmacy partners.
This article was authored by Eduard Cristea and clinically reviewed by Dr. A. Goher, MD. Health Technology Researcher & Publisher. See our methodology and affiliate disclosure.